Inadequate Response in Major Depressive Disorder: Optimizing Outcomes with Adjunctive Antipsychotic Therapy

Duration

1.25 hr

Profession

Pharmacy

# of Credits

1.25

Accreditation

CCCEP

Expiry Date

2021-09-23

Major depressive disorder has a major impact on ability to function and has a negative impact on quality of life. MDD is a leading cause of disability throughout the world and is a major contributor to the overall global burden of disease.

Treatment outcomes can be poor, with less than half of those treated achieving remission. A failure to regain pre-morbid level of function is common and impacts both the person and their love ones.

This program includes two case-based modules, the first of which will review treatment initiation and optimization in MDD based on the CANMAT guidelines, with a focus on the advantages and disadvantages of different treatment alternatives.The second case-based module will review the evidence supporting different management options for optimizing treatment of MDD and will review the atypical antipsychotic treatment options for adjunctive therapy in MDD.

​This continuing education lesson is designed primarily for pharmacists and has been accredited by the Canadian Council on Continuing Education in Pharmacy (CCCEP) for 1.25 CEU(s). CCCEP File Number: 1066-2020-3088-I-P

N/A

Serge Lessard, MD, FRCPC

Sheryl Horton-Smith

Ajit Johal, BSP RPh BCPP CDE CTH

Upon completion of this learning program participants will be better able to:

  • Identify patients with inadequate response to treatment for major depressive disorder.
  • Distinguish the pharmacological approaches for managing inadequate response to treatment for major depressive disorder.
  • Differentiate the antipsychotic treatment options for adjunctive therapy in major depressive disorder.
  • Develop an approach to counselling patients about adjunctive therapy in major depressive disorder.



Related Courses